Nasal decongestants and cardiovascular health: an underestimated risk ratio

Nasal decongestants, such as pseudoephedrine and oxymetazoline, are widely used medications to relieve nasal congestion associated with colds, flu, and allergic rhinitis. These substances act as vasoconstrictors, reducing blood flow in the nasal mucosa vessels through the stimulation of α-adrenergic receptors, which promotes immediate decongestion. Although effective in symptom relief, these medications carry risks, particularly concerning the cardiovascular system. Vasoconstriction can lead to increased blood pressure, tachycardia, and, in more severe cases, cardiac arrhythmias. These effects are especially concerning for individuals with pre-existing cardiovascular conditions, hypertension, diabetes, or other chronic diseases. Additionally, prolonged or excessive use may result in rhinitis medicational, a condition characterized by dependency on the medication and worsening of nasal congestion. Vulnerable populations, such as the elderly, pregnant women, and individuals with comorbidities, require special caution when using these medications. It is essential that their use be limited to the necessary period and under medical supervision, taking into account the associated risks. Therefore, understanding the potential cardiovascular side effects is crucial to promoting the rational use of these medications and preventing complications, ensuring safe and effective management of respiratory symptoms.